Susceptibility of Cutibacterium acnes to topical minocycline foam

Sutcliffe, Joyce A.; McLaughlin, Robert E.; Webster, Guy F.; Read, Andrew F.; Drlica, Karl; Elliott, Russell; Stuart, Iain

doi:10.1016/j.anaerobe.2020.102169

Cited by 12 publications

(10 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…45,46 In examining the effect of minocycline foam on C. acnes isolates, minocycline foam was found to be fourfold more active than bacitracin and tetracycline, eightfold more active than clindamycin, and ≥32-fold more active than erythromycin or neomycin. 42 In addition, minocycline foam had a lower resistance rate to C. acnes than the other antibiotics. 42…”

Section: Mechanism Of Actionmentioning

confidence: 97%

“…42 In addition, minocycline foam had a lower resistance rate to C. acnes than the other antibiotics. 42…”

Section: Mechanism Of Actionmentioning

confidence: 97%

“…41 Minocycline binds to the 30S subunit of bacterial ribosomes preventing protein synthesis and has with activity against both Gram-positive and Gram-negative bacteria including C. acnes. 42,43 The oral tetracyclines are lipid-soluble and can traverse the blood brain barrier, cause liver toxicity, impact tooth and bone development, and can induce hyperpigmentation leading to the broad side effect profile of the medication. The topical formulation was recently developed in an effort to provide the desired mechanism locally without having the unwanted side effects of oral antibiotics.…”

Section: Mechanism Of Actionmentioning

confidence: 99%

See 2 more Smart Citations

New medications for the treatment of acne

Horissian

Zaenglein

2021

Dermatological Reviews

View full text Add to dashboard Cite

Several new medications, both with novel molecules and modified delivery systems, have been developed for the treatment of acne vulgaris. Trifarotene 0.005% cream, tretinoin 0.05% lotion, and tazarotene 0.045% lotion expand topical retinoid options while minocycline 4% foam and systemic sarecycline provide new antibiotic choices for patients. Clascoterone 1% cream is a first in class topical antiandrogen recently FDA approved for acne. This review provides an update on these medications, including their mechanism of action, clinical data, and where they currently fit in the acne treatment algorithm as well as practical application tips.

show abstract

Section: Mechanism Of Actionmentioning

confidence: 97%

“…42 In addition, minocycline foam had a lower resistance rate to C. acnes than the other antibiotics. 42…”

Section: Mechanism Of Actionmentioning

confidence: 97%

Section: Mechanism Of Actionmentioning

confidence: 99%

See 1 more Smart Citation

New medications for the treatment of acne

Horissian

Zaenglein

2021

Dermatological Reviews

View full text Add to dashboard Cite

show abstract

“…This notion was supported by findings in a study on the susceptibility of C acnes to minocycline in FMX101, which demonstrated in vitro suppression of C acnes resistance. 9…”

Section: Foam Formulation and Preclinical Evaluation Of Minocycline Pmentioning

confidence: 99%

“…This notion was supported by findings in a study on the susceptibility of C acnes to minocycline in FMX101, which demonstrated in vitro suppression of C acnes resistance. 9 In a study on the epidermal penetration of minocycline applied as the 4% foam in an in vitro porcine skin model, most of the medication remained unabsorbed on the skin surface. 10 However, significant amounts accumulated in the skin upon application of the foam for 24 hours, with a greater amount (~1054 µg/g) found in the stratum corneum compared with the viable skin layers (~34.9 µg/g).…”

Section: Foam Formulation and Preclinical Evaluation Of Minocycline Pmentioning

confidence: 99%

Minocycline Topical Foam: A New Drug for the Treatment of Acne

Onge

Mobley

2020

Ann Pharmacother

View full text Add to dashboard Cite

Objective: To review the safety and efficacy of minocycline 4% topical foam for the treatment of moderate to severe acne vulgaris in adults and pediatric patients aged 9 years and older. Data Sources: A literature search through PubMed and EMBASE was conducted using the following keywords: FMX101, minocycline, foam, and acne. Study Selection and Data Extraction: Articles selected included those describing preclinical and clinical studies of pharmacokinetics, efficacy, or safety of topical minocycline foam. Data Synthesis: Minocycline 4% topical foam was shown in a preclinical study to effectively deliver minocycline to the pilosebaceous unit, with little penetration beyond the stratum corneum. This was consistent with a phase 1 pharmacokinetic study of the foam, which yielded a significantly reduced systemic exposure of minocycline compared with oral minocycline. In phase 2 and phase 3 clinical trials, the foam significantly reduced acne lesion counts and Investigator’s Global Assessment scores of acne severity compared with placebo. The foam has a good safety profile, with headache, mild erythema, hyperpigmentation, and mild dryness among the most common adverse effects. Relevance to Patient Care and Clinical Practice: Topical antibiotics have been a mainstay of acne therapy with the benefit of less systemic exposure compared with oral antibiotics. However, the development of bacterial resistance has reduced their use, thereby reducing options for many patients with acne. Minocycline 4% topical foam is a safe and effective alternative, which may help restore this important therapeutic approach for treating acne vulgaris.

show abstract

Topical Minocycline Foam 4%: A Review in Acne Vulgaris

Paik

2020

Am J Clin Dermatol

View full text Add to dashboard Cite

Susceptibility of Cutibacterium acnes to topical minocycline foam

Cited by 12 publications

References 43 publications

New medications for the treatment of acne

New medications for the treatment of acne

Minocycline Topical Foam: A New Drug for the Treatment of Acne

Topical Minocycline Foam 4%: A Review in Acne Vulgaris

Contact Info

Product

Resources

About